LipoScience (FRA:LI0) Change In Receivables : €1.95 Mil (TTM As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is LipoScience Change In Receivables?

LipoScience's change in receivables for the quarter that ended in Sep. 2014 was €0.36 Mil. It means LipoScience's Accounts Receivable declined by €0.36 Mil from Jun. 2014 to Sep. 2014 .

LipoScience's change in receivables for the fiscal year that ended in Dec. 2013 was €-0.49 Mil. It means LipoScience's Accounts Receivable increased by €0.49 Mil from Dec. 2012 to Dec. 2013 .

LipoScience's Accounts Receivable for the quarter that ended in Sep. 2014 was €3.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. LipoScience's Days Sales Outstanding for the three months ended in Sep. 2014 was 41.39.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. LipoScience's liquidation value for the three months ended in Sep. 2014 was €14.76 Mil.

LipoScience Change In Receivables Historical Data

The historical data trend for LipoScience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LipoScience Change In Receivables Chart

LipoScience Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Change In Receivables

-0.63

-1.09

0.36

-0.49

LipoScience Quarterly Data
	Mar11	Jun11	Dec11	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Change In Receivables	Get a 7-Day Free Trial								0.25	0.50	-0.01	1.09	0.36

LipoScience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.95 Mil.

LipoScience (FRA:LI0) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

LipoScience's Days Sales Outstanding for the quarter that ended in Sep. 2014 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3.014	/	6.644	*	91
=	41.39

2. In Ben Graham's calculation of liquidation value, LipoScience's accounts receivable are only considered to be worth 75% of book value:

LipoScience's liquidation value for the quarter that ended in Sep. 2014 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	31.037	-	18.612	+	0.75 * 3.014	+	0.5 * 0.154
=	14.76

LipoScience Change In Receivables Related Terms

Thank you for viewing the detailed overview of LipoScience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

LipoScience (FRA:LI0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LipoScience Inc (FRA:LI0) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.liposcience.com

LipoScience Inc was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. The Company is a clinical diagnostic company into field of personalized diagnostics based on nuclear magnetic resonance technology. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration, and directly measures the number of low density lipoprotein, particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. NMR detectors, or spectrometers, analyze a blood plasma or serum sample by subjecting it to a short pulse of radio frequency energy within a strong magnetic field. The Company currently markets NMR LipoProfile test through a direct sales force in 27 states. The Company competes against companies that offer other methods for measuring lipoproteins. Its competitors include Quest Diagnostics, Berkeley HeartLab, Inc., Atherotech, Inc. and SpectraCell Laboratories. The Company is subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of its business.

LipoScience (FRA:LI0) Headlines

No Headlines